Sodium arsenite induced biochemical perturbations in rats: ameliorating effect of curcumin.
The present study was undertaken to evaluate the therapeutic efficacy of curcumin in terms of normalization of altered biochemical parameters following sodium arsenite treatment in rats. Animals were divided into four groups. The first group was used as control. While, groups 2, 3 and 4 were orally treated with curcumin (Cur, 15 mg/kg BW), sodium arsenite (Sa, 5 mg/kg BW) and sodium arsenite plus curcumin, respectively. Results showed that the activities of transaminases and phosphatases were significantly decreased in liver due to Sa administration, whereas increased in plasma. The activity of brain and plasma acetylcholinesterase (AChE) was decreased in rats treated with Sa. Also, Sa significantly decreased plasma total protein (TP), albumin (Alb) and high density lipoprotein-cholesterol (HDL-c), while increased glucose, urea, creatinine, bilirubin, total lipid (TL), cholesterol, triglyceride (TG) and low density lipoprotein-cholesterol (LDL-c). Curcumin alone decreased the levels of glucose, urea, creatinine, TL, cholesterol, TG and LDL-c. Curcumin reduced Sa-induced transaminases, phosphatases, glucose, urea, creatinine, bilirubin, TL, cholesterol and TG. Moreover, curcumin induced Sa-reduced liver transaminases and phosphatases, plasma and brain AChE, and the levels of TP and Alb. Experimental results, therefore suggested that curcumin protects arsenic induced biochemical alterations in rats.
Yousef
Mokhtar I
MI
Department of Home Economic, Faculty of Specific Education, Alexandria University, 14 Mohamed Amin Shohaib Street, Moustafa Kamel, P.O. Box Roushdi, Alexandria 21529, Egypt. yousefmokhtar@yahoo.com
El-Demerdash
Fatma M
FM
Radwan
Fatma M E
FM
D000110:Acetylcholinesterase / Q000097:blood / Q000378:metabolism; D000410:Alanine Transaminase / Q000378:metabolism; D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D018053:Arsenites / Q000494:pharmacology*; D001663:Bilirubin / Q000378:metabolism; D001774:Blood Chemical Analysis; D001786:Blood Glucose / Q000378:metabolism; D001921:Brain / Q000187:drug effects / Q000201:enzymology* / Q000378:metabolism; D003404:Creatinine / Q000097:blood; D003474:Curcumin / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D050356:Lipid Metabolism / Q000187:drug effects; D008055:Lipids / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000201:enzymology* / Q000378:metabolism; D008297:Male; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D017670:Sodium Compounds / Q000494:pharmacology*; D014508:Urea / Q000097:blood
D018053:Arsenites; D001786:Blood Glucose; D004791:Enzyme Inhibitors; D008055:Lipids; D017670:Sodium Compounds; C017947:sodium arsenite; D014508:Urea; D003404:Creatinine; D000410:Alanine Transaminase; D000110:Acetylcholinesterase; D000469:Alkaline Phosphatase; D003474:Curcumin; D001663:Bilirubin